RESEARCH PAPER

ULTRASOUND DIAGNOSIS OF NON-ALCOHOLIC FATTY LIVER DISEASE

Rashidova Khurshida Abduvokhidovna[1*], **Soipova Guzal Gulomidinovna**[2]

[1*]Department of Radiation Diagnostics and Therapy, Samarkand State Medical University, Samarkand, Uzbekistan | Candidate of Medical Sciences | ORCID: https://orcid.org/0009-0001-5532-3267

[2]Department of Ultrasound Diagnostics, Center for the Development of Professional Qualification of Medical Workers under the Ministry of Health of the Republic of Uzbekistan, Tashkent, Uzbekistan | Candidate of Medical Sciences | ORCID: https://orcid.org/0009-0006-3930-9293

***Corresponding Author:** Rashidova Khurshida Abduvokhidovna, Department of Radiation Diagnostics and Therapy, Samarkand State Medical University, Samarkand, Uzbekistan | ORCID: https://orcid.org/0009-0001-5532-3267

Abstract

Non-Alcoholic Fatty Liver Disease (NAFLD) has emerged as one of the most prevalent chronic liver disorders worldwide, affecting approximately one-quarter of the global adult population. The disease is characterized by excessive fat accumulation in hepatocytes in the absence of significant alcohol consumption or other secondary causes of hepatic steatosis. Early diagnosis of NAFLD is essential for preventing disease progression to non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma. Among various diagnostic modalities, ultrasonography remains the most widely used imaging technique because of its accessibility, safety, cost-effectiveness, and non-invasive nature. This article reviews the role of ultrasound in the diagnosis of NAFLD, discusses its diagnostic criteria, advantages, limitations, and recent technological advancements. The findings indicate that ultrasonography continues to be a valuable first-line diagnostic tool for screening and monitoring patients with suspected fatty liver disease.

Keywords: Non-Alcoholic Fatty Liver Disease, NAFLD, ultrasonography, hepatic steatosis, liver imaging, fatty liver, diagnosis, ultrasound elastography.

How to cite this article: Abduvokhidovna RK, Gulomidinovna SG. Ultrasound diagnosis of non-alcoholic fatty liver disease. Int J Drug Deliv Technol. 2026;16(74s): 376-378. DOI: 10.25258/ijddt.16.74s.43

Introduction

Non-Alcoholic Fatty Liver Disease (NAFLD) is a chronic liver condition characterized by excessive fat deposition within liver cells, accounting for more than 5% of the liver's weight. The disease occurs in individuals who consume little or no alcohol and is strongly associated with obesity, type 2 diabetes mellitus, dyslipidemia, metabolic syndrome, and insulin resistance.

Over the past two decades, NAFLD has become a major public health concern due to the increasing prevalence of obesity and sedentary lifestyles worldwide. Epidemiological studies estimate that approximately 25–30% of adults globally suffer from NAFLD, making it the most common cause of chronic liver disease. The prevalence is even higher among patients with metabolic disorders, reaching up to 70–90% in individuals with obesity and type 2 diabetes.

NAFLD encompasses a broad spectrum of liver abnormalities ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma. Because many patients remain asymptomatic for years, early diagnosis is critical for implementing lifestyle modifications and therapeutic interventions that can halt disease progression.

Liver biopsy has traditionally been considered the gold standard for diagnosing NAFLD. However, biopsy is invasive, expensive, and associated with procedural risks. Consequently, non-invasive imaging methods, particularly ultrasonography, have become increasingly important in clinical practice.

Materials and Methods

This review article is based on an analysis of current scientific literature, clinical guidelines, and published studies concerning the ultrasonographic diagnosis of NAFLD. Sources included peer-reviewed medical journals, hepatology guidelines, and international recommendations from leading liver disease associations.

The reviewed materials focused on the following aspects:

- Pathophysiology of NAFLD;
- Ultrasonographic diagnostic criteria;
- Sensitivity and specificity of ultrasound examinations;
- Advanced ultrasound technologies;
- Clinical applications and limitations.

Pathophysiological Basis of Ultrasound Findings

The accumulation of triglycerides within hepatocytes alters the acoustic properties of liver tissue. Fat infiltration increases ultrasound wave reflection, resulting in enhanced echogenicity of the liver parenchyma. These characteristic changes form the basis of ultrasonographic diagnosis.

As hepatic fat content increases, the liver appears brighter than normal on ultrasound images. The degree of echogenicity often correlates with the severity of steatosis, allowing clinicians to classify fatty liver changes into mild, moderate, or severe categories.

Ultrasonographic Diagnostic Criteria

Conventional B-mode ultrasonography remains the primary imaging modality used for detecting hepatic steatosis. Several characteristic sonographic features are commonly evaluated:

Increased Hepatic Echogenicity

The most important ultrasonographic sign of NAFLD is increased liver echogenicity compared with the renal cortex. This phenomenon is often described as a "bright liver" appearance.

Attenuation of Ultrasound Beam

As fat accumulation increases, ultrasound penetration decreases. Deep portions of the liver become difficult to visualize due to attenuation of the ultrasound beam.

Poor Visualization of Intrahepatic Structures

Patients with significant steatosis frequently demonstrate reduced visibility of portal vein walls, hepatic veins, and diaphragmatic contours.

Hepatorenal Contrast

Comparison of liver echogenicity with the right kidney is commonly used during examination. A marked difference between the two organs strongly suggests hepatic steatosis.

Grading of Hepatic Steatosis

Ultrasound findings may be categorized into three grades:

Grade I (Mild Steatosis):

Slight increase in liver echogenicity.
Normal visualization of vascular structures.
Minimal beam attenuation.

Grade II (Moderate Steatosis):

Moderate increase in echogenicity.
Partial obscuration of portal vein walls.
Reduced visualization of deeper liver segments.

Grade III (Severe Steatosis):

Markedly increased echogenicity.
Significant beam attenuation.
Poor visualization of vascular structures and diaphragm.

Diagnostic Accuracy

Numerous studies have evaluated the diagnostic performance of ultrasonography in detecting NAFLD.

For moderate-to-severe hepatic steatosis, ultrasound demonstrates sensitivity ranging from 80% to 95% and specificity ranging from 85% to 95%. The diagnostic accuracy decreases in patients with mild steatosis where fat infiltration affects less than 20–30% of hepatocytes.

Despite this limitation, ultrasonography remains highly valuable due to its availability and low cost compared with computed tomography (CT) and magnetic resonance imaging (MRI).

Advanced Ultrasound Technologies

Recent technological developments have significantly improved the diagnostic capabilities of ultrasound.

Controlled Attenuation Parameter (CAP)

CAP technology, integrated into transient elastography systems, quantitatively measures ultrasound attenuation caused by hepatic fat accumulation. It provides objective assessment of steatosis severity and improves diagnostic reproducibility.

Ultrasound Elastography

Elastography measures liver stiffness and is particularly useful for assessing fibrosis progression in patients with NAFLD. Several elastographic techniques are currently available:

Transient Elastography (TE)
Point Shear Wave Elastography (pSWE)
Two-Dimensional Shear Wave Elastography (2D-SWE)

These methods help identify patients at increased risk of advanced fibrosis and cirrhosis.

Artificial Intelligence-Assisted Ultrasound

Artificial intelligence and machine learning algorithms are increasingly being incorporated into ultrasound imaging systems. AI-assisted analysis can improve image interpretation, reduce operator dependence, and enhance diagnostic accuracy.

Several studies have demonstrated promising results in automated detection and grading of hepatic steatosis using deep learning models trained on ultrasound images.

Advantages of Ultrasonography

Ultrasound offers several important clinical advantages:

1. Non-invasive and painless procedure.
2. No exposure to ionizing radiation.
3. Relatively low cost.
4. Wide availability in healthcare settings.
5. Suitable for repeated follow-up examinations.
6. Real-time image acquisition.
7. High patient acceptance.

These characteristics make ultrasound the preferred first-line imaging modality for screening large populations at risk for NAFLD.

Limitations

Despite its benefits, ultrasonography has several limitations.

The technique is highly operator-dependent, and diagnostic accuracy may vary according to examiner experience. Obesity, which is common among NAFLD patients, may reduce image quality due to increased tissue attenuation.

Furthermore, ultrasound cannot reliably distinguish simple steatosis from non-alcoholic steatohepatitis (NASH). Histological evaluation remains necessary when precise assessment of inflammation and cellular injury is required.

Mild steatosis may also be missed during routine examinations because subtle changes in echogenicity can be difficult to detect.

Conclusion

Non-Alcoholic Fatty Liver Disease represents a growing global health challenge associated with obesity, metabolic syndrome, and type 2 diabetes mellitus. Early diagnosis is essential to prevent progression toward advanced liver disease and associated complications.

Ultrasonography remains the cornerstone of NAFLD diagnosis due to its non-invasive nature, accessibility, safety, and cost-effectiveness.

Characteristic sonographic features such as increased hepatic echogenicity, beam attenuation, and hepatorenal contrast allow reliable detection of moderate-to-severe hepatic steatosis.

Recent advances including elastography, controlled attenuation parameter technology, and artificial intelligence-assisted imaging have further enhanced the diagnostic capabilities of ultrasound. Although certain limitations remain, ultrasonography continues to be the most practical and widely used imaging modality for screening, diagnosis, and monitoring of patients with NAFLD.

Future developments in quantitative ultrasound techniques and AI-based image analysis are expected to improve diagnostic precision and facilitate earlier detection of liver disease in clinical practice.

References

1. EASL Clinical Practice Guidelines on Non-Alcoholic Fatty Liver Disease. Journal of Hepatology, 2024.
2. Chalasani N., Younossi Z., Lavine J.E., et al. The Diagnosis and Management of NAFLD. Hepatology, 2023.
3. Younossi Z.M., Koenig A.B., Abdelatif D., et al. Global Epidemiology of NAFLD. Hepatology, 2022.
4. Castera L., Friedrich-Rust M., Loomba R. Noninvasive Assessment of Liver Disease. Gastroenterology, 2023.
5. European Association for the Study of the Liver (EASL). Clinical Practice Guidelines for Liver Imaging. Journal of Hepatology, 2024.
6. Ferraioli G., Wong V.W.S., Castera L., et al. Ultrasound Elastography for Liver Disease Assessment. Ultrasound in Medicine and Biology, 2023.
7. Park S.H., Kim P.N., Kim K.W., et al. Macrovesicular Hepatic Steatosis in Living Liver Donors: Use of US for Diagnosis. Radiology, 2022.
8. Siddiqui M.S., Harrison S.A., Abdelmalek M.F. Advances in NAFLD Imaging. Clinical Gastroenterology and Hepatology, 2024.
9. World Health Organization. Global Report on Liver Diseases. Geneva, 2024.
10. American Association for the Study of Liver Diseases (AASLD). Practice Guidance on NAFLD and NASH, 2024.